GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » EV-to-EBIT

Vivesto AB (Vivesto AB) EV-to-EBIT : 0.24 (As of May. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vivesto AB's Enterprise Value is $-2.89 Mil. Vivesto AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.26 Mil. Therefore, Vivesto AB's EV-to-EBIT for today is 0.24.

The historical rank and industry rank for Vivesto AB's EV-to-EBIT or its related term are showing as below:

OASMY' s EV-to-EBIT Range Over the Past 10 Years
Min: -95.21   Med: -8.07   Max: -0.01
Current: -0.68

During the past 13 years, the highest EV-to-EBIT of Vivesto AB was -0.01. The lowest was -95.21. And the median was -8.07.

OASMY's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.86 vs OASMY: -0.68

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Vivesto AB's Enterprise Value for the quarter that ended in Dec. 2023 was $-3.92 Mil. Vivesto AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.26 Mil. Vivesto AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 312.48%.


Vivesto AB EV-to-EBIT Historical Data

The historical data trend for Vivesto AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB EV-to-EBIT Chart

Vivesto AB Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.40 -93.26 -8.62 -0.28 -1.10

Vivesto AB Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.11 -0.18 -0.17 -1.10

Competitive Comparison of Vivesto AB's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vivesto AB's EV-to-EBIT falls into.



Vivesto AB EV-to-EBIT Calculation

Vivesto AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-2.893/-12.262
=0.24

Vivesto AB's current Enterprise Value is $-2.89 Mil.
Vivesto AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivesto AB  (OTCPK:OASMY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Vivesto AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-12.262/-3.92404
=312.48 %

Vivesto AB's Enterprise Value for the quarter that ended in Dec. 2023 was $-3.92 Mil.
Vivesto AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivesto AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Vivesto AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB (Vivesto AB) Business Description

Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB (Vivesto AB) Headlines

From GuruFocus